Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ADN011
MIFTS: 65

Adenoid Cystic Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Adenoid Cystic Carcinoma

About this section

MalaCards integrated aliases for Adenoid Cystic Carcinoma:

Name: Adenoid Cystic Carcinoma 11 19 75 5 14 16 71
Adenoid Cystic Carcinoma of Salivary Gland 71
Carcinoma, Adenoid Cystic 43
Eccrine Dermal Cylindroma 71
Carcinoma Adenoid Cystic 53
Adenocystic Carcinoma 19
Carcinoma, Cribriform 71
Cribriform Carcinoma 19
Cylindroma 19

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Immune diseases Gastrointestinal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 11 DOID:0080202
MeSH 43 D003528
NCIt 49 C2970
UMLS 71 C0010606 C0205643 C0279751 more
Sources

Summaries for Adenoid Cystic Carcinoma

About this section

GARD: 19 Adenoid cystic carcinoma (ACC) is a rare form of adenocarcinoma, a type of cancer that begins in glandular tissues. It most commonly arises in the major and minor salivary glands of the head and neck. It can also occur in the breast, uterus, or other locations in the body. Symptoms depend on the tumor's location. Salivary gland tumors may cause painless masses in the mouth or face. Tumors of the lacrimal gland may cause a bulging eye or changes in vision. Those affecting the windpipe or voice box may cause respiratory symptoms or changes in speech, respectively. Advanced tumors may cause pain and/or nerve paralysis, as ACC often spreads along the nerves. It may also spread through the bloodstream. It spreads to the lymph nodes in about 5% to 10% of cases. The cause of ACC is currently unknown. It typically does not run in families.

MalaCards based summary: Adenoid Cystic Carcinoma, also known as adenoid cystic carcinoma of salivary gland, is related to cervical adenoid cystic carcinoma and lung adenoid cystic carcinoma, and has symptoms including pain An important gene associated with Adenoid Cystic Carcinoma is NFIB (Nuclear Factor I B), and among its related pathways/superpathways are Gene expression (Transcription) and ERK Signaling. The drugs Acetylcysteine and Vorinostat have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, breast and trachea, and related phenotypes are Decreased viability and Increased shRNA abundance (Z-score > 2)

Disease Ontology: 11 An adenocarcinoma that is characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells.

Wikipedia: 75 Adenoid cystic carcinoma is a rare type of cancer that can exist in many different body sites. This... more...
Sources

Related Diseases for Adenoid Cystic Carcinoma

About this section

Diseases related to Adenoid Cystic Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 785)
# Related Disease Score Top Affiliating Genes
1 cervical adenoid cystic carcinoma 33.5 NFIB MYB KRT7 KIT
2 lung adenoid cystic carcinoma 33.2 NFIB MYBL1 MYB KRT7 KIT
3 laryngeal adenoid cystic carcinoma 33.2 KRT7 KIT
4 salivary gland adenoid cystic carcinoma 33.1 TP53 NFIB MYBL1 KRT7 KIT
5 breast adenoid cystic carcinoma 33.0 NFIB MYBL1 KRT7 KIT ERBB2
6 bartholin's gland adenoid cystic carcinoma 33.0 PIK3CA NFIB MYBL1 KRT7 CREBBP
7 paranasal sinus cancer 32.8 TP53 KRT7 IDH1
8 sublingual gland adenoid cystic carcinoma 32.8 NFIB KRT7
9 ceruminous adenocarcinoma 32.5 MYBL1 KRT7 KIT
10 salivary gland carcinoma 31.7 TP53 NFIB MYBL1 KRT7 KIT ERBB2
11 adenoma 31.7 TP53 PIK3CA KRT7 KRAS HRAS AKT1
12 squamous cell carcinoma, head and neck 31.6 TP53 PTEN PIK3CA LRRC56 HRAS FBXW7
13 basal cell carcinoma 31.5 TP53 PTEN NOTCH1 KRT7 CREBBP AKT1
14 adenocarcinoma 31.5 TP53 PTEN PIK3CA NOTCH1 KRT7 KRAS
15 basaloid squamous cell carcinoma 31.4 TP53 KRT7 KIT
16 cribriform carcinoma 31.4 NFIB KRT7 KIT ERBB2
17 small cell carcinoma 31.4 TP53 PTEN KRT7
18 head and neck cancer 31.3 TP53 PTEN PIK3CA NOTCH1 KRAS HRAS
19 epithelial-myoepithelial carcinoma 31.3 NFIB KRT7 KIT
20 vulva cancer 31.3 TP53 PTEN PIK3CA KRT7 KIT HRAS
21 ductal carcinoma in situ 31.3 TP53 PTEN PIK3CA NOTCH1 ERBB2 AKT1
22 breast ductal carcinoma 31.3 TP53 PTEN KRT7 ERBB2
23 pleomorphic adenoma carcinoma 31.3 TP53 NFIB MYBL1 ERBB2
24 adenoid basal cell carcinoma 31.2 KRT7 KIT
25 skin benign neoplasm 31.1 TP53 KRT7 HRAS
26 squamous cell carcinoma 31.1 TP53 PTEN PIK3CA NOTCH1 KRT7 KRAS
27 papilloma 31.1 TP53 PTEN KRT7 KRAS ERBB2 AKT1
28 breast adenomyoepithelioma 31.0 PIK3CA KRT7 HRAS
29 mucosal melanoma 31.0 PTEN KIT HRAS
30 skin carcinoma 31.0 TP53 PTEN NOTCH1 KRT7 KIT HRAS
31 exanthem 31.0 KRAS KIT HRAS ERBB2 AKT1
32 meningioma, familial 31.0 TP53 PTEN PIK3CA NOTCH1 KIT IDH1
33 small cell cancer of the lung 31.0 TP53 PTEN PIK3CA KRT7 KIT AKT1
34 sarcoma 30.9 TP53 PIK3CA KRAS KIT HRAS
35 parotid gland cancer 30.9 TP53 ERBB2
36 cervix carcinoma 30.9 TP53 PTEN PIK3CA KRT7 KRAS HRAS
37 neuroblastoma 30.9 TP53 PTEN PIK3CA NOTCH1 KIT HRAS
38 sweat gland cancer 30.9 TP53 KRT7 KIT ERBB2
39 necrotizing sialometaplasia 30.8 TP53 KRT7
40 leukemia 30.8 TP53 NOTCH1 KIT IDH1 ERBB2 CREBBP
41 gastrointestinal stromal tumor 30.7 TP53 PTEN PIK3CA KRAS KIT HRAS
42 basal cell nevus syndrome 30.7 TP53 PTEN NOTCH1 HRAS AKT1
43 thyroid gland anaplastic carcinoma 30.7 TP53 PTEN PIK3CA KIT HRAS AKT1
44 breast malignant phyllodes tumor 30.7 TP53 KIT ERBB2
45 cervical squamous cell carcinoma 30.7 TP53 PTEN PIK3CA KRAS FBXW7
46 lung benign neoplasm 30.7 TP53 KRT7 KRAS HRAS
47 breast metaplastic carcinoma 30.7 TP53 KRT7 ERBB2
48 hypertrophy of breast 30.7 TP53 PTEN PIK3CA ERBB2 AKT1
49 cervical adenocarcinoma 30.6 TP53 KRT7 KRAS
50 lymphoma, non-hodgkin, familial 30.6 TP53 PIK3CA NOTCH1 MYB AKT1

Graphical network of the top 20 diseases related to Adenoid Cystic Carcinoma:



Diseases related to Adenoid Cystic Carcinoma
Sources

Symptoms & Phenotypes for Adenoid Cystic Carcinoma

About this section

UMLS symptoms related to Adenoid Cystic Carcinoma:


pain

GenomeRNAi Phenotypes related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

25 (show all 31)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.27 HRAS KRAS PIK3CA
2 Decreased viability GR00055-A-2 10.27 HRAS KRAS PIK3CA
3 Decreased viability GR00055-A-3 10.27 KRAS
4 Decreased viability GR00106-A-0 10.27 KRAS
5 Decreased viability GR00221-A-1 10.27 AKT1 HRAS KIT KRAS PIK3CA
6 Decreased viability GR00221-A-2 10.27 AKT1 HRAS KRAS PIK3CA
7 Decreased viability GR00221-A-3 10.27 AKT1 HRAS
8 Decreased viability GR00221-A-4 10.27 AKT1 PIK3CA
9 Decreased viability GR00249-S 10.27 AKT1
10 Decreased viability GR00301-A 10.27 KIT KRAS
11 Decreased viability GR00381-A-1 10.27 KRAS
12 Decreased viability GR00402-S-2 10.27 PIK3CA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.62 NFIB
14 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.62 KRAS
15 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.62 FBXW7
16 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.62 FBXW7
17 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.62 BCOR NFIB
18 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.62 FBXW7
19 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.62 BCOR
20 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.62 AKT1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.62 KRAS
22 Increased shRNA abundance (Z-score > 2) GR00366-A-28 9.62 MYB
23 Increased shRNA abundance (Z-score > 2) GR00366-A-34 9.62 NFIB
24 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.62 FBXW7
25 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.62 AKT1 PIK3CA
26 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.62 KRAS
27 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.62 AKT1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.62 BCOR
29 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.62 AKT1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-95 9.62 BCOR
31 Decreased viability in pancreas lineage GR00235-A 9.26 IDH1 KRT7 MYBL1 TP53

MGI Mouse Phenotypes related to Adenoid Cystic Carcinoma:

45 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.51 AKT1 ARID2 CREBBP ERBB2 FBXW7 HRAS
2 growth/size/body region MP:0005378 10.48 AKT1 BCOR CREBBP ERBB2 FBXW7 HRAS
3 nervous system MP:0003631 10.44 AKT1 BCOR CREBBP ERBB2 FBXW7 HRAS
4 endocrine/exocrine gland MP:0005379 10.41 AKT1 BCOR CREBBP ERBB2 FBXW7 HRAS
5 normal MP:0002873 10.38 AKT1 CREBBP ERBB2 FBXW7 HRAS KIT
6 neoplasm MP:0002006 10.35 AKT1 CREBBP ERBB2 FBXW7 HRAS KIT
7 cellular MP:0005384 10.35 AKT1 ARID2 BCOR CREBBP ERBB2 FBXW7
8 cardiovascular system MP:0005385 10.33 AKT1 ARID2 BCOR CREBBP ERBB2 FBXW7
9 muscle MP:0005369 10.32 AKT1 ARID2 CREBBP ERBB2 HRAS KIT
10 immune system MP:0005387 10.31 AKT1 ARID2 BCOR CREBBP FBXW7 IDH1
11 embryo MP:0005380 10.3 AKT1 BCOR CREBBP ERBB2 FBXW7 KIT
12 digestive/alimentary MP:0005381 10.29 BCOR CREBBP ERBB2 FBXW7 HRAS KIT
13 behavior/neurological MP:0005386 10.25 AKT1 BCOR CREBBP ERBB2 HRAS KIT
14 liver/biliary system MP:0005370 10.23 AKT1 CREBBP FBXW7 KIT KRAS MYB
15 craniofacial MP:0005382 10.19 BCOR CREBBP ERBB2 FBXW7 HRAS KIT
16 respiratory system MP:0005388 10.18 AKT1 CREBBP ERBB2 FBXW7 HRAS IDH1
17 limbs/digits/tail MP:0005371 10.11 BCOR CREBBP ERBB2 KIT KRAS PTEN
18 skeleton MP:0005390 10.07 AKT1 BCOR CREBBP ERBB2 HRAS IDH1
19 reproductive system MP:0005389 10.06 AKT1 ERBB2 FBXW7 KIT KRAS LRRC56
20 hematopoietic system MP:0005397 10 AKT1 BCOR CREBBP ERBB2 FBXW7 IDH1
21 mortality/aging MP:0010768 9.91 AKT1 ARID2 BCOR CREBBP ERBB2 FBXW7
22 integument MP:0010771 9.5 AKT1 BCOR CREBBP ERBB2 FBXW7 HRAS
Sources

Drugs & Therapeutics for Adenoid Cystic Carcinoma

About this section

Drugs for Adenoid Cystic Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 90)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 2 616-91-1 581 12035
2
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
3
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
4
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
5
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
6
Cetuximab Approved Phase 1, Phase 2 205923-56-4
7
Erlotinib Approved, Investigational Phase 1, Phase 2 183319-69-9, 183321-74-6 176870
8
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
9
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908
10
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
11
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
12
Dexrazoxane Approved, Withdrawn Phase 2 24584-09-6 71384
13
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
14
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
15
Nelfinavir Approved Phase 2 159989-64-7 64143
16
Nivolumab Approved Phase 2 946414-94-4
17
Ipilimumab Approved Phase 2 477202-00-9
18
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
19
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
20
Avelumab Approved, Investigational Phase 2 1537032-82-8
21
Lenvatinib Approved, Investigational Phase 2 417716-92-8 9823820
22
Aspartic acid Approved, Nutraceutical Phase 1, Phase 2 56-84-8 5960
23
Arginine Approved, Investigational, Nutraceutical Phase 1, Phase 2 74-79-3 6322
24
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
25
Isotretinoin Approved, Investigational, Nutraceutical Phase 2 302-79-4, 4759-48-2 5538 444795 5282379
26
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 2 133585-56-5, 60-18-4, 556-02-5 1153 6057
27
Rivoceranib Investigational Phase 2 811803-05-1 11315474
28
Imatinib Mesylate Phase 2 220127-57-1
29 Antiviral Agents Phase 2
30 Anti-Infective Agents Phase 2
31 Expectorants Phase 2
32 Antidotes Phase 2
33 N-monoacetylcystine Phase 2
34 Respiratory System Agents Phase 2
35 Antioxidants Phase 2
36 Protective Agents Phase 2
37 Histone Deacetylase Inhibitors Phase 2
38 Immunoglobulins, Intravenous Phase 2
39 Angiogenesis Inhibitors Phase 2
40 Anti-Bacterial Agents Phase 2
41 Antibiotics, Antitubercular Phase 2
42 Liposomal doxorubicin Phase 2
43 Antimetabolites Phase 2
44 Immunosuppressive Agents Phase 2
45
Razoxane Phase 2
46 Radiopharmaceuticals Phase 1, Phase 2
47 Antihypertensive Agents Phase 2
48 Neurotransmitter Agents Phase 1, Phase 2
49
Arginyl-glycyl-aspartic acid Phase 1, Phase 2 3328704
50 Fluorodeoxyglucose F18 Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 76)
# Name Status NCT ID Phase Drugs
1 Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma of All Anatomic Sites of Origin and Non-adenoid Cystic Carcinoma Malignant Tumors of the Salivary Gland Unknown status NCT03146650 Phase 2
2 Phase II Study of Apatinib Mesylate Administered as a Daily Oral Treatment in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck Unknown status NCT02775370 Phase 2 Apatinib Mesylate
3 Phase II Study of Imatinib (Glivec) Administered as a Daily Oral Treatment in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck Overexpressing KIT Unknown status NCT00180921 Phase 2 Imatinib
4 Combined Treatment of Adenoid Cystic Carcinoma With Cetuximab and IMRT Plus C12 Heavy Ion Boost - ACCEPT - (ACC, Erbitux, and Particle Therapy); Phase I/II Feasibility Study Unknown status NCT01192087 Phase 1, Phase 2 Cetuximab
5 A Phase II Randomized Trial of Efficacy and Safety of Particle Therapy With or Without Apatinib as Induction Therapy for Treatment of Head and Neck Adenoid Cystic Carcinoma Unknown status NCT02942693 Phase 2 Apatinib
6 Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety Unknown status NCT02883374 Phase 2 Chidamide
7 A Randomized, Double-Blind Pilot Study of N-Acetylcysteine Mucoadherent Rinse Versus Placebo for Thickened Secretions and Mucositis Secondary to Chemoradiotherapy in the Management of Head and Neck Malignancies Completed NCT02123511 Phase 2 acetylcysteine
8 A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Subjects With Locally Advanced, Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC) Completed NCT01175980 Phase 2 Vorinostat
9 A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Completed NCT01604772 Phase 2 Akt Inhibitor MK2206
10 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
11 Phase II Trial of PS-341 (NSC 681239) Followed by the Addition of Doxorubicin at Progression in Advanced Adenoid Cystic Carcinoma of the Head and Neck Completed NCT00077428 Phase 2 bortezomib;doxorubicin hydrochloride
12 A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
13 A Phase II Study of DOVitinib in REcurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands (DOVE) Completed NCT01678105 Phase 2 Dovitinib
14 A Phase 2 Study of GW572016 in Recurrent and/or Metastatic Adenoid Cystic Carcinoma, and Other EGFR-and/or erbB2-expressing Malignant Tumors of the Salivary Glands Completed NCT00095563 Phase 2 lapatinib ditosylate
15 Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors Completed NCT00859937 Phase 2 Dasatinib
16 A Phase II Trial of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma Completed NCT03087019 Phase 2 Pembrolizumab
17 Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Head and Neck Adenoid Cystic Carcinoma Completed NCT00581360 Phase 2 doxorubicin and bortezomib
18 A Phase 2 Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT00886132 Phase 2 Sunitinib
19 Chidamide Combined With Cisplatin in Recurrent or Metastatic Head and Neck Adenoid Cystic Carcinoma: A Prospective, Open-label, Phase II Study of a Single Center Completed NCT03639168 Phase 2 Chidamide combined with cisplatin
20 A Phase II Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma Completed NCT03999684 Phase 2 Tretinoin
21 Phase II Study On Gemcitabine In Recurrent Or Metastatic Adenoid Cystic Carcinoma Of The Head And Neck Completed NCT00017498 Phase 2 gemcitabine hydrochloride
22 A Phase II Pilot Study of Dovitinib (TKI258) in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. Completed NCT01524692 Phase 2 Dovitinib (TKI258)
23 A Phase II Study of Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Completed NCT01558661 Phase 2 AG-013736 (AXITINIB)
24 Randomized Phase II Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma Completed NCT02859012 Phase 2 Axitinib
25 Phase II Study of RAD001monotherapy in Patients With Unresectable Adenoid Cystic Carcinoma Completed NCT01152840 Phase 2 RAD001
26 Phase II Study of TKI258 (Dovitinib) Monotherapy in Patients With Unresectable Adenoid Cystic Carcinoma Completed NCT01417143 Phase 2 TKI258 (Dovitinib):
27 Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Completed NCT01806675 Phase 1, Phase 2 18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
28 A Phase II Trial of the HIV Protease Inhibitor Nelfinavir in Patients With Recurrent Symptomatic Adenoid Cystic Cancers of the Head and Neck Completed NCT01065844 Phase 2 Nelfinavir
29 Phase II Study on Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands of the Upper Aerodigestive Tract Completed NCT02860936 Phase 2 Lenvatinib
30 A Phase 2 Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma (ACC) Recruiting NCT03990571 Phase 2 Avelumab;Axitinib
31 Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation Recruiting NCT04214366 Phase 2
32 A Phase II Study of Lenvatinib Plus Pembrolizumab in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma and Other Salivary Gland Cancers Recruiting NCT04209660 Phase 2 Lenvatinib;Pembrolizumab
33 A Prospective, Open-label, Randomized Controlled Clinical Study to Evaluate the Efficacy and Safety of All-trans Retinoic Acid (ATRA) in the Treatment of Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck Recruiting NCT04433169 Phase 2 All-trans Retinoic Acid;VEGFR inhibitor;Chemotherapy
34 Tyrosine Kinase Inhibitors in the Management of Local Advanced or Metastastic Adenoid Cystic Carcinoma Recruiting NCT04974866 Phase 2 EGFR-TK Inhibitor
35 Phase II Study to Evaluate Amivantamab in Recurrent and Metastatic Adenoid Cystic Carcinoma Recruiting NCT05074940 Phase 2 Amivantamab
36 Lutetium-177-PSMA Radioligand Therapy for Advanced Salivary Gland Cancer, a Phase II Pilot Study. Recruiting NCT04291300 Phase 2 Lutetium-177-PSMA-I&T
37 Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001) Recruiting NCT04140526 Phase 1, Phase 2 ONC-392;Pembrolizumab
38 A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study With Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adult Patients With Locally Advanced or Metastatic Solid Tumours and Haematological Malignancies Characterised by Alterations of the NOTCH Signalling Pathway Recruiting NCT03422679 Phase 1, Phase 2 CB-103
39 Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma Recruiting NCT05010629 Phase 2 9-ING-41;Carboplatin
40 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
41 A Phase 2, Open-Label, Multi-center Study of AL101 in Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations Active, not recruiting NCT03691207 Phase 2 AL101
42 A Phase II Study of Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Active, not recruiting NCT02098538 Phase 2 Regorafenib
43 A Phase 2 Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Rivoceranib in Subjects With Recurrent or Metastatic Adenoid Cystic Carcinoma of All Anatomic Sites of Origin Active, not recruiting NCT04119453 Phase 2 Rivoceranib
44 A Phase II Study of Lenvatinib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Active, not recruiting NCT02780310 Phase 2 Lenvatinib
45 Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma Withdrawn NCT04832438 Phase 2 9-ING-41;Carboplatin
46 A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer Completed NCT00470496 Phase 1 HPPH;photodynamic therapy
47 A Phase I Study Of Bevacizumab (Recombinant Humanized Monoclonal Antibody To Vascular Endothelial Growth Factor) In Addition To Flourouracil And Hydroxyurea As Initial Chemotherapy With Concomitant Radiotherapy (B-FHX) For Poor Prognosis Head And Neck Cancer Completed NCT00023959 Phase 1 hydroxyurea;fluorouracil
48 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
49 Phase 1 Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, NSC #707545) in Patients With Solid Tumors. Completed NCT00089362 Phase 1 alvespimycin hydrochloride
50 A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride

Search NIH Clinical Center for Adenoid Cystic Carcinoma

Cochrane evidence based reviews: carcinoma, adenoid cystic

Sources

Genetic Tests for Adenoid Cystic Carcinoma

About this section
Sources

Anatomical Context for Adenoid Cystic Carcinoma

About this section

Organs/tissues related to Adenoid Cystic Carcinoma:

MalaCards : Salivary Gland, Breast, Trachea, Lung, Uterus, Brain, Eye
Sources

Publications for Adenoid Cystic Carcinoma

About this section

Articles related to Adenoid Cystic Carcinoma:

(show top 50) (show all 5987)
# Title Authors PMID Year
1
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 5
26619011 2016
2
C-kit gene mutations in adenoid cystic carcinoma are rare. 53 62
20514080 2010
3
Value of p63 and podoplanin (D2-40) immunoreactivity in the distinction between primary cutaneous tumors and adenocarcinomas metastatic to the skin: a clinicopathologic and immunohistochemical study of 79 cases. 53 62
20377670 2010
4
Expression of c-kit and Slug correlates with invasion and metastasis of salivary adenoid cystic carcinoma. 53 62
20219417 2010
5
Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl. 53 62
20227366 2010
6
Prognostic value of quantitative p63 immunostaining in adenoid cystic carcinoma of salivary gland assessed by computerized image analysis. 53 62
19877114 2010
7
Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). 53 62
19574086 2009
8
Differential expression of galectin-3, beta-catenin, and cyclin D1 in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary glands. 53 62
19659475 2009
9
Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland. 53 62
19617878 2009
10
Immunohistochemical differentiation of four benign eccrine tumors. 53 62
18564284 2009
11
Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas. 53 62
18983466 2008
12
Loss of Maspin expression is a negative prognostic factor in common salivary gland tumors. 53 62
17936671 2008
13
Effect of exogenous bFGF on the proliferation of human adenoid cystic carcinoma ACC-2 cells. 53 62
18481005 2008
14
[Effects of basic fibroblast growth factor on the proliferation of human salivary adenoid cystic carcinoma cell line ACC-2 and extracellular signal-regulated kinase, Cyclin D1, p2waf/cip1 signaling pathway]. 53 62
18605443 2008
15
[Prognostic value of immunohistochemistry in salivary gland cancer]. 53 62
18214402 2008
16
Hierarchical cluster analysis of myoepithelial/basal cell markers in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma. 53 62
18084258 2008
17
Primary adenoid cystic carcinoma of the lung: absence of KIT mutations. 53 62
17932891 2007
18
Expression of neural cell adhesion molecule in salivary adenoid cystic carcinoma and its correlation with perineural invasion. 53 62
17982624 2007
19
Cylindromatosis and the CYLD gene: new lessons on the molecular principles of epithelial growth control. 53 62
18008375 2007
20
[Expression and significance of E-cadherin in adenoid cystic carcinoma of the salivary glands]. 53 62
17927866 2007
21
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. 53 62
17761983 2007
22
Galectin-3 immunoprofile in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary glands. 53 62
16996782 2007
23
Relative frequency of intra-oral minor salivary gland tumors: a study of 380 cases from northern California and comparison to reports from other parts of the world. 53 62
17391298 2007
24
[Effect of mechanical stimulation on the expression of E-cadherin/cateninin complex in salivary adenoid cystic carcinoma]. 53 62
17375572 2007
25
Application of alpha-smooth muscle actin and c-kit in the differential diagnosis of adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. 53 62
16807072 2007
26
A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. 53 62
16757202 2007
27
Adenoid cystic carcinoma of the buccal vestibule: A case report and review of the literature. 53 62
16996786 2006
28
Immunophenotypic overlap between adenoid cystic carcinoma and collagenous spherulosis of the breast: potential diagnostic pitfalls using myoepithelial markers. 53 62
16810311 2006
29
[Expression of Pin1, beta-catenin and cyclin D1 in salivary adenoid cystic carcinoma and its significance]. 53 62
17129455 2006
30
Knockdown of Sox4 expression by RNAi induces apoptosis in ACC3 cells. 53 62
16636670 2006
31
Aberrant expression of beta-catenin, Pin1 and cylin D1 in salivary adenoid cystic carcinoma: relation to tumor proliferation and metastasis. 53 62
16865250 2006
32
Protein expression profiling identifies maspin and stathmin as potential biomarkers of adenoid cystic carcinoma of the salivary glands. 53 62
16094606 2006
33
Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours. 53 62
16140564 2006
34
Expression of galectin-3 in adenoid cystic carcinoma of the head and neck and its relationship with distant metastasis. 53 62
16184379 2006
35
KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. 53 62
16258515 2005
36
Clinical prognostic factors in malignant parotid gland tumors. 53 62
16274796 2005
37
Induction of apoptosis in human salivary gland tumor cells by anti-NCAM antibody. 53 62
16211277 2005
38
Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast. 53 62
15846389 2005
39
Expressions of nuclear factor kappaB, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome. 53 62
16243805 2005
40
Differential KIT expression in histological subtypes of adenoid cystic carcinoma (ACC) of the salivary gland. 53 62
16054424 2005
41
Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. 53 62
16135502 2005
42
KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. 53 62
16082245 2005
43
Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma. 53 62
15959912 2005
44
Cylindroma (dermal analog tumor) of the breast: a comparison with cylindroma of the skin and adenoid cystic carcinoma of the breast. 53 62
15899777 2005
45
[Expression and significance of cyclin D1 in human adenoid cystic carcinoma]. 53 62
16078452 2005
46
Expression of IgSF in salivary adenoid cystic carcinoma and its relationship with invasion and metastasis. 53 62
15817073 2005
47
Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays. 53 62
15863127 2005
48
Adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of minor salivary glands: a comparative immunohistochemical study using the epithelial membrane and carcinoembryonic antibodies. 53 62
15888109 2005
49
Expression of beta-catenin, E-cadherin and cyclin D1 in adenoid cystic carcinoma of the salivary gland. 53 62
15943036 2005
50
P53, bcl-2 and Ki-67 expression in adenoid cystic carcinoma of the palate. A clinico-pathologic study of 21 cases with long-term follow-up. 53 62
15792122 2005
Sources

Variations for Adenoid Cystic Carcinoma

About this section

ClinVar genetic disease variations for Adenoid Cystic Carcinoma:

5 (show top 50) (show all 59)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MYB, NFIB t(6;9)(q23.3;p22.3) TRANS Pathogenic
 495138 GRCh37: 6:135515857-135515858
GRCh38:
2 MYB, NFIB t(6;9)(q23.3;p22.3) TRANS Pathogenic
 495139 GRCh37: 6:135516358-135516359
GRCh38:
3 MYBL1, NFIB t(8;9)(q13.1;p22.3) TRANS Pathogenic
 495136 GRCh37: 8:67501293-67501294
GRCh38:
4 MYB, NFIB t(6;9)(q23.3;p22.3) TRANS Pathogenic
 495140 GRCh37: 6:135516423-135516424
GRCh38:
5 MYB, NFIB t(6;9)(q23.3;p22.3) TRANS Pathogenic
 495137 GRCh37: 6:135522688-135522689
GRCh38:
6 KRAS NM_004985.5(KRAS):c.34G>C (p.Gly12Arg) SNV Pathogenic
 12579 rs121913530 GRCh37: 12:25398285-25398285
GRCh38: 12:25245351-25245351
7 BCOR NM_001123385.2(BCOR):c.4787_4802del (p.Gly1596fs) DEL Likely Pathogenic
 495132 rs1555913337 GRCh37: X:39913526-39913541
GRCh38: X:40054273-40054288
8 BCOR NM_001123385.2(BCOR):c.4063G>T (p.Glu1355Ter) SNV Likely Pathogenic
 495127 rs780712297 GRCh37: X:39922109-39922109
GRCh38: X:40062856-40062856
9 ARID2 NM_152641.4(ARID2):c.2989C>T (p.Gln997Ter) SNV Likely Pathogenic
 495130 rs1555155110 GRCh37: 12:46244895-46244895
GRCh38: 12:45851112-45851112
10 NOTCH1 NM_017617.5(NOTCH1):c.4045_4052del (p.Ala1349fs) DEL Likely Pathogenic
 495129 rs1554728034 GRCh37: 9:139400296-139400303
GRCh38: 9:136505844-136505851
11 HRAS, LRRC56 NM_005343.4(HRAS):c.35G>C (p.Gly12Ala) SNV Likely Pathogenic
 12603 rs104894230 GRCh37: 11:534288-534288
GRCh38: 11:534288-534288
12 IDH1 NM_005896.4(IDH1):c.395G>A (p.Arg132His) SNV Likely Pathogenic
 156444 rs121913500 GRCh37: 2:209113112-209113112
GRCh38: 2:208248388-208248388
13 HRAS, LRRC56 NM_005343.4(HRAS):c.34G>T (p.Gly12Cys) SNV Likely Pathogenic
 12613 rs104894229 GRCh37: 11:534289-534289
GRCh38: 11:534289-534289
14 TP53 NM_000546.6(TP53):c.637C>G (p.Arg213Gly) SNV Likely Pathogenic
 376651 rs397516436 GRCh37: 17:7578212-7578212
GRCh38: 17:7674894-7674894
15 TP53 NM_000546.6(TP53):c.451C>A (p.Pro151Thr) SNV Likely Pathogenic
 12369 rs28934874 GRCh37: 17:7578479-7578479
GRCh38: 17:7675161-7675161
16 TP53 NM_000546.6(TP53):c.638G>C (p.Arg213Pro) SNV Likely Pathogenic
 231214 rs587778720 GRCh37: 17:7578211-7578211
GRCh38: 17:7674893-7674893
17 TP53 NM_000546.6(TP53):c.451C>G (p.Pro151Ala) SNV Likely Pathogenic
 376641 rs28934874 GRCh37: 17:7578479-7578479
GRCh38: 17:7675161-7675161
18 TP53 NM_000546.6(TP53):c.451C>T (p.Pro151Ser) SNV Likely Pathogenic
 12370 rs28934874 GRCh37: 17:7578479-7578479
GRCh38: 17:7675161-7675161
19 CREBBP NM_004380.3(CREBBP):c.4336C>T (p.Arg1446Cys) SNV Likely Pathogenic
 95047 rs398124146 GRCh37: 16:3788618-3788618
GRCh38: 16:3738617-3738617
20 HRAS, LRRC56 NM_005343.4(HRAS):c.34G>A (p.Gly12Ser) SNV Likely Pathogenic
 12602 rs104894229 GRCh37: 11:534289-534289
GRCh38: 11:534289-534289
21 TP53 NM_000546.6(TP53):c.638G>A (p.Arg213Gln) SNV Likely Pathogenic
 135359 rs587778720 GRCh37: 17:7578211-7578211
GRCh38: 17:7674893-7674893
22 NOTCH1 NM_017617.5(NOTCH1):c.2825G>A (p.Cys942Tyr) SNV Likely Pathogenic
 495128 rs1554728658 GRCh37: 9:139404329-139404329
GRCh38: 9:136509877-136509877
23 BCOR NM_001123385.2(BCOR):c.398_399insAC (p.Ala134fs) INSERT Likely Pathogenic
 495125 rs1555919960 GRCh37: X:39934200-39934201
GRCh38: X:40074947-40074948
24 SF3B1 NM_012433.4(SF3B1):c.1873C>G (p.Arg625Gly) SNV Likely Pathogenic
 376536 rs775623976 GRCh37: 2:198267484-198267484
GRCh38: 2:197402760-197402760
25 SF3B1 NM_012433.4(SF3B1):c.1874G>A (p.Arg625His) SNV Likely Pathogenic
 376534 rs1057519961 GRCh37: 2:198267483-198267483
GRCh38: 2:197402759-197402759
26 SF3B1 NM_012433.4(SF3B1):c.1873C>T (p.Arg625Cys) SNV Likely Pathogenic
 376535 rs775623976 GRCh37: 2:198267484-198267484
GRCh38: 2:197402760-197402760
27 PIK3CA NM_006218.4(PIK3CA):c.3127A>G (p.Met1043Val) SNV Likely Pathogenic
 376485 rs1057519936 GRCh37: 3:178952072-178952072
GRCh38: 3:179234284-179234284
28 PIK3CA NM_006218.4(PIK3CA):c.1258T>G (p.Cys420Gly) SNV Likely Pathogenic
 376469 rs121913272 GRCh37: 3:178927980-178927980
GRCh38: 3:179210192-179210192
29 PIK3CA NM_006218.4(PIK3CA):c.3128T>C (p.Met1043Thr) SNV Likely Pathogenic
 376486 rs1057519937 GRCh37: 3:178952073-178952073
GRCh38: 3:179234285-179234285
30 PIK3CA NM_006218.4(PIK3CA):c.1033A>C (p.Asn345His) SNV Likely Pathogenic
 376490 rs1057519939 GRCh37: 3:178921551-178921551
GRCh38: 3:179203763-179203763
31 PIK3CA NM_006218.4(PIK3CA):c.1034A>C (p.Asn345Thr) SNV Likely Pathogenic
 376489 rs1057519938 GRCh37: 3:178921552-178921552
GRCh38: 3:179203764-179203764
32 PIK3CA NM_006218.4(PIK3CA):c.1034A>T (p.Asn345Ile) SNV Likely Pathogenic
 376488 rs1057519938 GRCh37: 3:178921552-178921552
GRCh38: 3:179203764-179203764
33 PIK3CA NM_006218.4(PIK3CA):c.3127A>T (p.Met1043Leu) SNV Likely Pathogenic
 376487 rs1057519936 GRCh37: 3:178952072-178952072
GRCh38: 3:179234284-179234284
34 IDH1 NM_005896.4(IDH1):c.394C>A (p.Arg132Ser) SNV Likely Pathogenic
 375893 rs121913499 GRCh37: 2:209113113-209113113
GRCh38: 2:208248389-208248389
35 FBXW7 NM_001349798.2(FBXW7):c.1393C>T (p.Arg465Cys) SNV Likely Pathogenic
 376414 rs867384286 GRCh37: 4:153249385-153249385
GRCh38: 4:152328233-152328233
36 FBXW7 NM_001349798.2(FBXW7):c.1394G>A (p.Arg465His) SNV Likely Pathogenic
 376415 rs1057519895 GRCh37: 4:153249384-153249384
GRCh38: 4:152328232-152328232
37 FBXW7 NM_001349798.2(FBXW7):c.1394G>T (p.Arg465Leu) SNV Likely Pathogenic
 376417 rs1057519895 GRCh37: 4:153249384-153249384
GRCh38: 4:152328232-152328232
38 CREBBP NM_004380.3(CREBBP):c.4336C>G (p.Arg1446Gly) SNV Likely Pathogenic
 376388 rs398124146 GRCh37: 16:3788618-3788618
GRCh38: 16:3738617-3738617
39 CREBBP NM_004380.3(CREBBP):c.4337G>T (p.Arg1446Leu) SNV Likely Pathogenic
 376386 rs1057519884 GRCh37: 16:3788617-3788617
GRCh38: 16:3738616-3738616
40 IDH1 NM_005896.4(IDH1):c.394C>G (p.Arg132Gly) SNV Likely Pathogenic
 375892 rs121913499 GRCh37: 2:209113113-209113113
GRCh38: 2:208248389-208248389
41 CREBBP NM_004380.3(CREBBP):c.4337G>A (p.Arg1446His) SNV Likely Pathogenic
 376387 rs1057519884 GRCh37: 16:3788617-3788617
GRCh38: 16:3738616-3738616
42 FBXW7 NM_001349798.2(FBXW7):c.1394G>C (p.Arg465Pro) SNV Likely Pathogenic
 376416 rs1057519895 GRCh37: 4:153249384-153249384
GRCh38: 4:152328232-152328232
43 FBXW7 NM_001349798.2(FBXW7):c.1393C>G (p.Arg465Gly) SNV Likely Pathogenic
 376418 rs867384286 GRCh37: 4:153249385-153249385
GRCh38: 4:152328233-152328233
44 IDH1 NM_005896.4(IDH1):c.395G>T (p.Arg132Leu) SNV Likely Pathogenic
 375889 rs121913500 GRCh37: 2:209113112-209113112
GRCh38: 2:208248388-208248388
45 PIK3CA NM_006218.4(PIK3CA):c.1035T>A (p.Asn345Lys) SNV Likely Pathogenic
 376050 rs121913284 GRCh37: 3:178921553-178921553
GRCh38: 3:179203765-179203765
46 IDH1 NM_005896.4(IDH1):c.394C>T (p.Arg132Cys) SNV Likely Pathogenic
 375891 rs121913499 GRCh37: 2:209113113-209113113
GRCh38: 2:208248389-208248389
47 PIK3CA NM_006218.4(PIK3CA):c.3129G>A (p.Met1043Ile) SNV Likely Pathogenic
 179173 rs121913283 GRCh37: 3:178952074-178952074
GRCh38: 3:179234286-179234286
48 PIK3CA NM_006218.4(PIK3CA):c.1258T>C (p.Cys420Arg) SNV Likely Pathogenic
 31945 rs121913272 GRCh37: 3:178927980-178927980
GRCh38: 3:179210192-179210192
49 TP53 NM_000546.6(TP53):c.638G>T (p.Arg213Leu) SNV Likely Pathogenic
 376650 rs587778720 GRCh37: 17:7578211-7578211
GRCh38: 17:7674893-7674893
50 TP53 NM_000546.6(TP53):c.452C>G (p.Pro151Arg) SNV Likely Pathogenic
 376640 rs1057520000 GRCh37: 17:7578478-7578478
GRCh38: 17:7675160-7675160

Cosmic variations for Adenoid Cystic Carcinoma:

8 (show top 50) (show all 36935)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM148982261 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2402C>T p.A801V 16:2074246-2074246 16
2 COSM151513835 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2402C>T p.A801V 16:2074246-2074246 16
3 COSM102618829 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2402C>T p.A801V 16:2074246-2074246 16
4 COSM87028709 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2402C>T p.A801V 16:2074246-2074246 16
5 COSM101181362 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2255C>T p.A752V 16:2074246-2074246 16
6 COSM151371079 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2402C>T p.A801V 16:2074246-2074246 16
7 COSM147692833 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2402C>T p.A801V 16:2074246-2074246 16
8 COSM136618137 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2435C>T p.A812V 16:2074246-2074246 16
9 COSM150576172 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2402C>T p.A801V 16:2074246-2074246 16
10 COSM149802491 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2402C>T p.A801V 16:2074246-2074246 16
11 COSM150314621 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2402C>T p.A801V 16:2074246-2074246 16
12 COSM110103993 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2291C>T p.A764V 16:2074246-2074246 16
13 COSM90404312 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2402C>T p.A801V 16:2074246-2074246 16
14 COSM151748035 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2402C>T p.A801V 16:2074246-2074246 16
15 COSM150355398 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2402C>T p.A801V 16:2074246-2074246 16
16 COSM151333958 TSC1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2684T>A p.V895D 9:132897552-132897552 16
17 COSM148034383 TSC1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2666T>A p.V889D 9:132897552-132897552 16
18 COSM150536749 TSC1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2531T>A p.V844D 9:132897552-132897552 16
19 COSM133086949 TSC1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2531T>A p.V844D 9:132897552-132897552 16
20 COSM149039376 TSC1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2681T>A p.V894D 9:132897552-132897552 16
21 COSM147983098 TSC1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2681T>A p.V894D 9:132897552-132897552 16
22 COSM85719495 TSC1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2684T>A p.V895D 9:132897552-132897552 16
23 COSM111040676 TSC1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2684T>A p.V895D 9:132897552-132897552 16
24 COSM150677254 TSC1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2669T>A p.V890D 9:132897552-132897552 16
25 COSM151875081 TSC1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2684T>A p.V895D 9:132897552-132897552 16
26 COSM143944858 TP53 salivary gland,major,carcinoma,adenoid cystic carcinoma c.109C>T p.R37* 17:7674945-7674945 16
27 COSM144653059 TP53 salivary gland,major,carcinoma,adenoid cystic carcinoma c.310G>A p.V104M 17:7675185-7675185 16
28 COSM142561802 TP53 salivary gland,major,carcinoma,adenoid cystic carcinoma c.310G>A p.V104M 17:7675185-7675185 16
29 COSM121877621 TP53 salivary gland,major,carcinoma,adenoid cystic carcinoma c.190C>T p.R64* 17:7674945-7674945 16
30 COSM142838067 TP53 salivary gland,major,carcinoma,adenoid cystic carcinoma c.586C>T p.R196* 17:7674945-7674945 16
31 COSM106054364 TP53 salivary gland,major,carcinoma,adenoid cystic carcinoma c.586C>T p.R196* 17:7674945-7674945 16
32 COSM122735020 TP53 salivary gland,major,carcinoma,adenoid cystic carcinoma c.190C>T p.R64* 17:7674945-7674945 16
33 COSM112255102 TP53 salivary gland,major,carcinoma,adenoid cystic carcinoma c.427G>A p.V143M 17:7675185-7675185 16
34 COSM122735247 TP53 salivary gland,major,carcinoma,adenoid cystic carcinoma c.319A>G p.N107D 17:7674248-7674248 16
35 COSM144014616 TP53 salivary gland,major,carcinoma,adenoid cystic carcinoma c.682A>G p.N228D 17:7674248-7674248 16
36 COSM144087903 TP53 salivary gland,major,carcinoma,adenoid cystic carcinoma c.238A>G p.N80D 17:7674248-7674248 16
37 COSM93184913 TP53 salivary gland,major,carcinoma,adenoid cystic carcinoma c.715A>G p.N239D 17:7674248-7674248 16
38 COSM96852092 TENT5C salivary gland,minor,carcinoma,adenoid cystic carcinoma c.833T>A p.F278Y 1:117623701-117623701 16
39 COSM93990925 STAG2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2405T>G p.I802S 23:124071195-124071195 16
40 COSM94060559 STAG2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2405T>G p.I802S 23:124071195-124071195 16
41 COSM94013793 STAG2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2405T>G p.I802S 23:124071195-124071195 16
42 COSM94116422 STAG2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2405T>G p.I802S 23:124071195-124071195 16
43 COSM86749613 STAG2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2405T>G p.I802S 23:124071195-124071195 16
44 COSM88093366 SOX9 salivary gland,major,carcinoma,adenoid cystic carcinoma c.1457T>A p.V486D 17:72124314-72124314 16
45 COSM151032994 SOX9 salivary gland,major,carcinoma,adenoid cystic carcinoma c.1457T>A p.V486D 17:72124314-72124314 16
46 COSM84674496 SMO salivary gland,major,carcinoma,adenoid cystic carcinoma c.385G>C p.V129L 7:129203437-129203437 16
47 COSM109727521 SMARCA4 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.2372C>T p.A791V 19:11013046-11013046 16
48 COSM89651491 SMARCA4 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.2372C>T p.A791V 19:11013046-11013046 16
49 COSM148658876 SMARCA4 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.2372C>T p.A791V 19:11013046-11013046 16
50 COSM138930030 SMARCA4 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.2372C>T p.A791V 19:11013046-11013046 16

Copy number variations for Adenoid Cystic Carcinoma from CNVD:

6 (show top 50) (show all 202)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13805 1 1 61300000 Deletion Adenoid cystic carcinoma
2 31809 1 31200000 32688000 Loss ADGRB2 Adenoid cystic carcinoma
3 31810 1 31200000 32688000 Loss EIF3I Adenoid cystic carcinoma
4 31811 1 31200000 32688000 Loss FABP3 Adenoid cystic carcinoma
5 31812 1 31200000 32688000 Loss HDAC1 Adenoid cystic carcinoma
6 31813 1 31200000 32688000 Loss IQCC Adenoid cystic carcinoma
7 31814 1 31200000 32688000 Loss KHDRBS1 Adenoid cystic carcinoma
8 31815 1 31200000 32688000 Loss LCK Adenoid cystic carcinoma
9 31816 1 31200000 32688000 Loss MARCKSL1 Adenoid cystic carcinoma
10 31817 1 31200000 32688000 Loss PTP4A2 Adenoid cystic carcinoma
11 31818 1 31200000 32688000 Loss PUM1 Adenoid cystic carcinoma
12 31819 1 31200000 32688000 Loss RBBP4 Adenoid cystic carcinoma
13 31820 1 31200000 32688000 Loss SERINC2 Adenoid cystic carcinoma
14 31821 1 31200000 32688000 Loss TXLNA Adenoid cystic carcinoma
15 33928 1 50618000 52179000 Loss CDKN2C Adenoid cystic carcinoma
16 33929 1 50618000 52179000 Loss EPS15 Adenoid cystic carcinoma
17 33930 1 50618000 52179000 Loss FAF1 Adenoid cystic carcinoma
18 33931 1 50618000 52179000 Loss NRDC Adenoid cystic carcinoma
19 33932 1 50618000 52179000 Loss RAB3B Adenoid cystic carcinoma
20 33933 1 50618000 52179000 Loss RNF11 Adenoid cystic carcinoma
21 50143 11 114500000 121200000 Deletion Adenoid cystic carcinoma
22 58545 11 68400000 70400000 Deletion Adenoid cystic carcinoma
23 61970 12 103800000 109000000 LOH Adenoid cystic carcinoma
24 64283 12 125900000 133851895 LOH Adenoid cystic carcinoma
25 67068 12 35800000 133851895 Loss Adenoid cystic carcinoma
26 67236 12 38200000 58100000 Deletion Adenoid cystic carcinoma
27 67639 12 43743000 50676000 Loss ACVR1B Adenoid cystic carcinoma
28 67640 12 43743000 50676000 Loss ACVRL1 Adenoid cystic carcinoma
29 67641 12 43743000 50676000 Loss ADCY6 Adenoid cystic carcinoma
30 67642 12 43743000 50676000 Loss AMIGO2 Adenoid cystic carcinoma
31 67643 12 43743000 50676000 Loss ANP32D Adenoid cystic carcinoma
32 67644 12 43743000 50676000 Loss ARF3 Adenoid cystic carcinoma
33 67645 12 43743000 50676000 Loss ATF1 Adenoid cystic carcinoma
34 67646 12 43743000 50676000 Loss CCNT1 Adenoid cystic carcinoma
35 67647 12 43743000 50676000 Loss COL2A1 Adenoid cystic carcinoma
36 67648 12 43743000 50676000 Loss DDX23 Adenoid cystic carcinoma
37 67649 12 43743000 50676000 Loss FAIM2 Adenoid cystic carcinoma
38 67650 12 43743000 50676000 Loss HDAC7 Adenoid cystic carcinoma
39 67651 12 43743000 50676000 Loss LALBA Adenoid cystic carcinoma
40 67652 12 43743000 50676000 Loss LETMD1 Adenoid cystic carcinoma
41 67653 12 43743000 50676000 Loss LIMA1 Adenoid cystic carcinoma
42 67654 12 43743000 50676000 Loss KMT2D Adenoid cystic carcinoma
43 67655 12 43743000 50676000 Loss PFKM Adenoid cystic carcinoma
44 67656 12 43743000 50676000 Loss PLEKHA8P1 Adenoid cystic carcinoma
45 67657 12 43743000 50676000 Loss PRKAG1 Adenoid cystic carcinoma
46 67658 12 43743000 50676000 Loss RACGAP1 Adenoid cystic carcinoma
47 67659 12 43743000 50676000 Loss RAPGEF3 Adenoid cystic carcinoma
48 67660 12 43743000 50676000 Loss RHEBL1 Adenoid cystic carcinoma
49 67661 12 43743000 50676000 Loss RND1 Adenoid cystic carcinoma
50 67662 12 43743000 50676000 Loss SENP1 Adenoid cystic carcinoma
Sources

Expression for Adenoid Cystic Carcinoma

About this section
Search GEO for disease gene expression data for Adenoid Cystic Carcinoma.
Sources

Pathways for Adenoid Cystic Carcinoma

About this section

Pathways related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 118)
# Super pathways Score Top Affiliating Genes
1
Gene expression (Transcription) 66
Show member pathways
 14.09 TP53 SF3B1 PTEN NOTCH1 NFIB MYBL1
2
ERK Signaling 64
Show member pathways
 13.89 AKT1 CREBBP ERBB2 HRAS KIT KRAS
3
Disease 66
Show member pathways
 13.84 AKT1 CREBBP ERBB2 FBXW7 HRAS IDH1
4
Signal Transduction 66
13.78 TP53 PTEN PIK3CA NOTCH1 MYB KRAS
5
Nervous system development 66
Show member pathways
 13.77 PIK3CA NOTCH1 MYB KRT7 KRAS HRAS
6
TGF-Beta Pathway 64
Show member pathways
 13.61 TP53 PIK3CA KRAS KIT HRAS ERBB2
7
Prolactin Signaling 64
Show member pathways
 13.54 AKT1 CREBBP ERBB2 HRAS KRAS PIK3CA
8
Akt Signaling 64
Show member pathways
 13.47 TP53 PTEN KRAS KIT HRAS ERBB2
9
CREB Pathway 64
Show member pathways
 13.39 PTEN KRAS KIT HRAS ERBB2 CREBBP
10
PAK Pathway 64
Show member pathways
 13.37 PTEN NOTCH1 KRAS KIT HRAS ERBB2
11
RAF/MAP kinase cascade 66
Show member pathways
 13.36 PTEN PIK3CA NOTCH1 KRAS KIT HRAS
12
PIP3 activates AKT signaling 66
Show member pathways
 13.14 TP53 PTEN PIK3CA KIT ERBB2 AKT1
13
Phospholipase-C Pathway 64
Show member pathways
 13.14 TP53 PTEN KRAS KIT HRAS CREBBP
14
ESR-mediated signaling 66
Show member pathways
 13.05 PIK3CA MYB KRAS HRAS CREBBP AKT1
15
PI3K-Akt signaling pathway 74
Show member pathways
 12.96 TP53 PTEN PIK3CA MYB KRAS KIT
16
NFAT and Cardiac Hypertrophy 64
Show member pathways
 12.93 PTEN PIK3CA KRAS HRAS ERBB2 CREBBP
17
IL-9 Signaling Pathways 65
Show member pathways
 12.92 PTEN PIK3CA KRAS HRAS AKT1
18
CCR5 Pathway in Macrophages 64
Show member pathways
 12.92 PIK3CA KRAS HRAS CREBBP AKT1
19
Toll-like receptor signaling pathway 74
Show member pathways
 12.92 TP53 PIK3CA KRAS HRAS CREBBP AKT1
20
Signaling by Receptor Tyrosine Kinases 66
12.91 PIK3CA KRAS KIT HRAS ERBB2 AKT1
21
Development Angiotensin activation of ERK 22
Show member pathways
 12.9 PIK3CA KRAS KIT HRAS AKT1
22
Pre-NOTCH Expression and Processing 66
Show member pathways
 12.84 TP53 NOTCH1 FBXW7 CREBBP AKT1
23
fMLP Pathway 64
Show member pathways
 12.83 TP53 KRAS HRAS CREBBP AKT1
24
Malignant pleural mesothelioma 74
12.77 AKT1 HRAS KIT PIK3CA PTEN TP53
25
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling 66
Show member pathways
 12.76 PTEN PIK3CA KIT ERBB2 AKT1
26
4-1BB Pathway 64
Show member pathways
 12.73 TP53 KRAS HRAS CREBBP AKT1
27
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.71 TP53 PIK3CA KRAS KIT HRAS AKT1
28
Immune response IL-23 signaling pathway 22
Show member pathways
 12.67 TP53 PIK3CA KRAS HRAS ERBB2 AKT1
29
Endometrial cancer 74
Show member pathways
 12.66 TP53 PTEN PIK3CA KRAS KIT HRAS
30
Hepatocyte growth factor receptor signaling 74
Show member pathways
 12.53 TP53 PTEN PIK3CA HRAS ERBB2 AKT1
31
Development EGFR signaling pathway 22
Show member pathways
 12.52 AKT1 ERBB2 HRAS KRAS PIK3CA TP53
32
NF-kappaB Pathway 70
Show member pathways
 12.5 AKT1 ERBB2 HRAS KRAS PIK3CA TP53
33
Development Dopamine D2 receptor transactivation of EGFR 22
Show member pathways
 12.48 PIK3CA KRAS HRAS AKT1
34
MAPK signaling pathway 74
12.47 TP53 KRAS HRAS AKT1
35
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.47 PIK3CA KRAS HRAS AKT1
36
Development FGFR signaling pathway 22
Show member pathways
 12.47 PIK3CA KRAS HRAS AKT1
37
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.46 PIK3CA KRAS KIT HRAS ERBB2
38
Development Ligand-independent activation of ESR1 and ESR2 22
Show member pathways
 12.41 PIK3CA HRAS ERBB2 CREBBP AKT1
39
Immune response Fc epsilon RI pathway 22
Show member pathways
 12.4 PTEN PIK3CA HRAS AKT1
40
B Cell Receptor Signaling Pathway 67
Show member pathways
 12.4 PTEN PIK3CA KRAS HRAS AKT1
41
Toll Comparative Pathway 64
Show member pathways
 12.38 TP53 PIK3CA HRAS AKT1
42
Signaling by VEGF 66
Show member pathways
 12.38 PIK3CA KRAS HRAS AKT1
43
Focal adhesion 74
12.37 PTEN PIK3CA HRAS ERBB2 AKT1
44
Development IGF-1 receptor signaling 22
Show member pathways
 12.35 TP53 PTEN PIK3CA HRAS AKT1
45
Ras signaling 74
12.33 PIK3CA KRAS KIT HRAS AKT1
46
Signaling by ERBB2 KD Mutants 66
Show member pathways
 12.32 PIK3CA KRAS HRAS ERBB2
47
VEGF Signaling Pathway 60 67
Show member pathways
 12.28 PTEN KRAS HRAS AKT1
48
GDNF-Family Ligands and Receptor Interactions 64
Show member pathways
 12.27 PIK3CA KRAS HRAS AKT1
49
NGF Pathway 64
Show member pathways
 12.26 TP53 KRAS HRAS CREBBP AKT1
50
Breast cancer pathway 74
Show member pathways
 12.24 TP53 PTEN PIK3CA NOTCH1 KRAS KIT
Sources

GO Terms for Adenoid Cystic Carcinoma

About this section

Biological processes related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.36 AKT1 CREBBP HRAS MYB MYBL1 NFIB
2 positive regulation of cell population proliferation GO:0008284 10.18 PTEN NOTCH1 KRAS KIT HRAS ERBB2
3 heart development GO:0007507 10.11 TP53 PTEN NOTCH1 ERBB2 BCOR
4 positive regulation of gene expression GO:0010628 10.06 AKT1 ERBB2 HRAS KIT KRAS NOTCH1
5 negative regulation of gene expression GO:0010629 9.9 TP53 PIK3CA NOTCH1 HRAS FBXW7 AKT1
6 regulation of cell population proliferation GO:0042127 9.8 TP53 NOTCH1 KIT HRAS ERBB2
7 cellular response to decreased oxygen levels GO:0036294 9.61 PTEN AKT1
8 phosphatidylinositol 3-kinase signaling GO:0014065 9.56 PTEN PIK3CA ERBB2 AKT1
9 cell population proliferation GO:0008283 9.23 TP53 PTEN NOTCH1 NFIB KRAS KIT
Sources

Sources for Adenoid Cystic Carcinoma

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....